CD86 and acute myeloid leukemia: As expected, OG86 treatment of THP1 AML cells promoted differentiation, as evidenced by reduced clonogenic potential and increased expression of the monocyte/macrophage lineage differentiation marker CD86 (used as a surrogate for differentiation in the experiments that follow) (Figures 4A–4D).